Lifestyle modifications should be the first-line approach and include: Eating smaller, more frequent meals rather than large portions that overwhelm the already-slowed digestive system Avoiding eating within 2-3 hours of bedtime to allow adequate time for gastric emptying before lying down Elevating the head of the bed by 6-8 inches using blocks or a wedge pillow to reduce nocturnal reflux Identifying and avoiding trigger foods such as caffeine, alcohol, chocolate, spicy foods, citrus, and high-fat meals Maintaining an upright posture for at least 2-3 hours after meals Wearing loose-fitting clothing that doesn't compress the abdomen Pharmacological management may be appropriate for patients with persistent symptoms despite lifestyle modifications
The patent picture Eli Lilly holds tirzepatide patents projected to extend into the early-to-mid 2030s, while Novo Nordisk's semaglutide patents are expected to expire around 2031-2033
LifeVantage calls this "dual activation and amplification." Here is how they break it down
Initially, we were concerned about an 8% error rate of the Xpert HCV VL FS test in the study of Lamoury et al
Novo May Have Just Built the Case to End Compound Semaglutide Im starting to believe that semaglutide will be added to the FDAs Demonstrable Difficulties for Compounding list
Understanding the latest research can also help patients have better conversations with their healthcare providers
